Incidence of type 2 diabetes in familial combined hyperlipidemia.


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
03 2020
Historique:
received: 09 12 2019
revised: 12 02 2020
accepted: 22 02 2020
entrez: 21 3 2020
pubmed: 21 3 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Familial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes (T2D) in a longitudinal cohort of FCHL pedigrees. FCHL patients, their unaffected relatives and spouses included in our baseline cohort in 1998-2005 (n=596) were re-invited to determine the incidence of self-reported T2D (that was confirmed by medical records), used as the primary outcome measure. The Fatty Liver Index (FLI) and Homeostasis Model Assessment Insulin Resistance (HOMA2-IR) were used as markers of fatty liver and insulin resistance, respectively. A subset of the original cohort underwent ultrasound of the liver, and subcutaneous and visceral fat in 2002-2005 (n=275; 'ultrasound subcohort'). Follow-up data (median: 15 years) was acquired for 76%. The incidence rate of T2D was significantly higher in FCHL patients compared with spouses (19.2 per 1000 person-years vs 2.8 per 1000 person-years; HR : 6.3, 95% CI: 2.4 to 16.8), whereas no differences were observed between unaffected relatives and spouses (HR: 0.9, 95% CI: 0.3 to 2.6). Cox's proportional hazard regression analyses showed that baseline HOMA2-IR and FLI≥60, but not waist circumference, BMI, or the FCHL affected state, were independently associated with incident T2D. Similar results were obtained in the ultrasound subcohort (median follow-up: 11 years), in which baseline HOMA2-IR and fatty liver (assessed by ultrasound) were independently associated with incident T2D. This study further corroborates the suggestion that the liver plays a central role in the pathogenesis of cardiometabolic complications in FCHL. It supports periodical screening for T2D in this high-risk population.

Identifiants

pubmed: 32193201
pii: 8/1/e001107
doi: 10.1136/bmjdrc-2019-001107
pmc: PMC7103854
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Diabetes Care. 2018 Feb;41(2):372-382
pubmed: 29358469
Int J Obes Relat Metab Disord. 2001 Sep;25(9):1346-51
pubmed: 11571598
J Lipid Res. 2006 Dec;47(12):2799-807
pubmed: 16971732
Diabetes. 2008 Aug;57(8):2253-7
pubmed: 18556336
Eur J Clin Invest. 2002 Feb;32(2):71-3
pubmed: 11895451
Am J Clin Nutr. 2006 Sep;84(3):483-9
pubmed: 16960160
J Clin Invest. 1973 Jul;52(7):1544-68
pubmed: 4718953
Clin Sci (Lond). 2007 Nov;113(9):375-81
pubmed: 17564583
Lancet. 2012 Aug 11;380(9841):565-71
pubmed: 22883507
N Engl J Med. 1993 Dec 30;329(27):1988-92
pubmed: 8247074
Gastroenterology. 2008 May;134(5):1369-75
pubmed: 18355813
Clin Biochem. 2004 Sep;37(9):785-90
pubmed: 15329317
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Atherosclerosis. 2019 Jan;280:1-6
pubmed: 30448567
Circ Cardiovasc Genet. 2010 Feb;3(1):31-8
pubmed: 20160193
Diabetes. 1985 Oct;34(10):1055-8
pubmed: 4043554
Diabetologia. 1997 Apr;40(4):454-62
pubmed: 9112023
Clin Sci (Lond). 2007 Jan;112(2):123-30
pubmed: 16958621
Neth J Med. 2010 Apr;68(4):163-7
pubmed: 20421657
Angiology. 2018 Mar;69(3):242-248
pubmed: 28681648
Atherosclerosis. 2001 Aug;157(2):481-9
pubmed: 11472750
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Gastroenterology. 2002 Sep;123(3):745-50
pubmed: 12198701
J Clin Invest. 2004 Jun;113(11):1582-8
pubmed: 15173884
Nat Rev Endocrinol. 2012 Feb 14;8(6):352-62
pubmed: 22330738
J Hypertens. 2009 May;27(5):1009-16
pubmed: 19402225
Diabetologia. 2006 Apr;49(4):755-65
pubmed: 16463046
Arterioscler Thromb Vasc Biol. 2005 May;25(5):1026-31
pubmed: 15731490
Diabetes Care. 2007 Jan;30(1):89-94
pubmed: 17192339
Curr Opin Lipidol. 2010 Dec;21(6):530-8
pubmed: 20739883
Diabetes Care. 1998 Dec;21(12):2191-2
pubmed: 9839117

Auteurs

Martijn C G J Brouwers (MCGJ)

Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands mcgj.brouwers@mumc.nl.

Jacqueline de Graaf (J)

Department of Internal Medicine, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, The Netherlands.

Nynke Simons (N)

Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Internal Medicine, Division of General Internal Medicine, Laboratory for Metabolism and Vascular Medicine, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.

Steven Meex (S)

Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, The Netherlands.

Sophie Ten Doeschate (S)

Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.

Shadana van Heertum (S)

Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.

Britt Heidemann (B)

Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.

Jim Luijten (J)

Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.

Douwe de Boer (D)

Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, The Netherlands.

Nicolaas Schaper (N)

Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.

Coen D A Stehouwer (CDA)

Department of Internal Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.

Marleen M J van Greevenbroek (MMJ)

Department of Internal Medicine, Division of General Internal Medicine, Laboratory for Metabolism and Vascular Medicine, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH